Multiple sclerosis with a progressive course from onset in Lorraine-Eastern France

• Published in: Journal of neurology Vol. 254; no. 10; pp. 1370 - 1375
• Main Authors: DEBOUVERIE, Marc, LOUIS, Sarah, PITTION-VOUYOVITCH, Sophie, ROEDERER, Thomas, VESPIGNANI, Hervé
• Format: Journal Article
• Language: English
• Published: Berlin Springer 01.10.2007; Springer Nature B.V
• Subjects: Adolescent; Adult; Age; Age of Onset; Aged; Biological and medical sciences; Cohort Studies; Disability Evaluation; Disease Progression; Epidemiology; Female; France - epidemiology; Gender; Humans; Immunomodulators; Magnetic resonance imaging; Male; Medical sciences; Middle Aged; Multiple sclerosis; Multiple Sclerosis - epidemiology; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis; Natural history; Neurology; Patients; Pharmacology. Drug treatments; Population-based studies; Regression Analysis; Retrospective Studies; Risk Factors; France; Europe; Disability; Multiple sclerosis; Nervous system diseases; Central nervous system disease; Sex; primary progressive course; Inflammatory disease
• ISSN: 0340-5354; 1432-1459
• DOI: 10.1007/s00415-007-0554-3

To investigate the patient characteristics, disease progression, and associated risk factors in patients with multiple sclerosis (MS) with a progressive onset, we conducted a longitudinal population-based study of 359 patients (252 with primary progressive MS (PPMS) and 107 with progressive relapsing MS (PRMS)) in Lorraine, France. As outcome measures, we assessed the time from MS onset to reaching disability status scale (DSS) scores of 4, 6 and 7 and the time from assignment of DSS score of 6 to assignment of DSS score of 7. We studied the influence on these outcomes of sex, age of onset and symptoms of onset. We also studied the influence of the time from MS onset to assignment of DSS 6 on the time from MS onset to assignment of DSS 7. There were no significant differences in the demographic data (gender and age at onset of MS) and clinical data (median time to DSS scores of 4, 6 and 7) between the patients with PPMS and PRMS suggesting such a distinction may be unnecessary. The male/female ratio in all 359 patients with MS with a progressive onset was 1/1.36. The median age at onset was 42.7 years (25% Q1 = 34.7; 75% Q3 = 50.0), was lower for male (40.5 years) than for female patients (44.2 years; p = 0.002). The median time to DSS scores of 4, 6 and 7 were (in years) 3.0 (95% CI = 2.8 to 3.7), 9.9 (95% CI = 9.0 to 10.6), and 17.0 (95% CI = 14.9 to 19.0). A cane was required in 25% of patients 5 years after onset and in 75% 15 years after onset. We did not find any significant unfluence of sex, age at onset, or symptoms at onset on the time from MS onset to assignment of scores 6 or 7 or on the time from the assignment of a score of 6 to the assignment of a score of 7.